Case Form
Find Out if You Potentially Qualify for a Financial Reward by filling out the form.
On October 4, 2024, Biodexa reported updated data on progression-free and overall survival from a Phase 1 study of its drug MX110 in the treatment of recurrent glioblastoma. Biodexa disclosed that of the four patients who were enrolled in Cohort A of the study, two are now deceased, with one achieving an overall survival of 12 months and the other 13 months since the start of treatment.
Follow this news, Biodexa’s stock price fell over 7% on the same day.